261G000311 - USTECINUMAB 45 MG SOL INJ BIOSIMILAR SE

This tender, identified by reference 261G000311, is for the acquisition of Ustekinumab 45 mg solution for injection, specifically a biosimilar version. Ustekinumab is a biologic medication used to treat certain autoimmune conditions, such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It works by targeting specific proteins (interleukin-12 and -23) involved in the inflammatory processes of these diseases. The requirement is for a biosimilar, which is a highly similar version of an already approved biologic drug, offering a potentially more cost-effective alternative while maintaining comparable safety and efficacy. The '45 mg SOL INJ' indicates the dosage strength and the formulation (solution for injection). The 'SE' likely denotes a specific market or regulatory designation. This procurement is typically made by healthcare providers, hospitals, or national health systems to ensure the availability of this important therapeutic agent for patients suffering from the specified chronic inflammatory conditions. The tender will detail the required quantities, quality standards, packaging, and delivery specifications.

This is a supplies contract in the health and medical services, information and communication technology and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 57,200.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.